Life SciencesLiability
Get a quote

TL;DR

Portland anchors the Oregon biotech cluster centered on Oregon Health & Science University (OHSU) spinouts and the Knight Cancer Institute. Cancer biotech focus with strong precision medicine and early-detection diagnostic programs. Insurance follows standard clinical-stage architecture with Oregon-specific privacy law overlay (OCPA) and OHSU TTO licensing terms baked into IP/E&O scope.

Portland biotech

Portland biotech insurance - OHSU spinouts, Knight Cancer Institute, Oregon Bioscience.

Portland anchors the Oregon biotech cluster centered on Oregon Health & Science University (OHSU) - one of the leading West Coast biomedical research institutions outside the Bay Area - and the OHSU Knight Cancer Institute. The cluster contributes spinouts across cancer biotech, immunology, and precision medicine programs.

Cluster characteristics

OHSU and Knight Cancer Institute anchor the cluster.

OHSU spinouts follow standard clinical-stage biotech architecture: D&O for VC-backed governance, clinical trial liability for active studies, IP/E&O for OHSU Technology Transfer Office licensing arrangements.

Knight Cancer Institute contributes cancer biotech spinouts with strong precision medicine and early-cancer-detection focus, in addition to traditional immuno-oncology and CAR-T operators.

Oregon Bioscience Association network operators run lean insurance programs at early-stage, scaling at funding rounds.

Regulatory overlay

Oregon-specific privacy and TTO terms.

Oregon Consumer Privacy Act (OCPA) applies to entities collecting personal data of Oregon residents above defined thresholds. Cyber programs should include explicit OCPA regulatory defense scope.

OHSU Technology Transfer Office license agreements require operating biotechs to name OHSU as additional insured, indemnify OHSU for commercial use of licensed IP, and maintain minimum coverage limits. IP indemnity scope is load-bearing in TTO arrangements.

Oregon clinical trial framework follows federal GCP standards. CTAs with OHSU and other Oregon AMCs are professional and structured but generally less aggressive than top-tier Boston or Bay Area AMC CTAs.

Market commentary

Premium environment and carrier appetite.

Portland biotech insurance pricing tracks the broader Pacific Northwest biotech market - generally favorable carrier appetite for cancer biotech and precision medicine programs, with specialty life-sciences carriers actively writing the segment.

Typical Series A clinical-stage Portland biotech runs $35K-$80K annual aggregate premium across D&O, CTL (if active), cyber, GL, and umbrella. Programs scale to $150K-$300K at Series C and IPO-readiness stages.

Carriers with strong OHSU-spinout placement experience price more competitively than generalist carriers; the OHSU TTO indemnity scope is well understood by the specialty market.

Frequently asked

Common questions from Portland-area biotech operators

How does OHSU Technology Transfer Office licensing affect biotech insurance?

OHSU TTO license agreements typically require the operating biotech to name OHSU as additional insured on products liability and clinical trial liability, indemnify OHSU for any commercial use of the licensed IP, and maintain minimum coverage limits scaled to the program stage. The IP indemnity scope is load-bearing - OHSU pushes for broad indemnity for any claim arising from the licensed IP, including third-party infringement. The biotech's E&O and general liability policies should be structured to respond to this scope.

What does a Knight Cancer Institute spinout typically need at Series A?

Cancer biotech spinouts from Knight typically need $2M-$5M D&O at Series A, $3M-$5M clinical trial liability if conducting active investigator-led work pre-IND, $5M cyber for PHI handling, and IP/E&O scaled to the licensing arrangement with OHSU. Early oncology indications (precision medicine, early-detection diagnostics) carry meaningfully different risk profiles than CAR-T or cell therapy programs at the same stage.

Does Oregon have any state-specific privacy laws that affect biotech cyber?

Oregon's Consumer Privacy Act (effective 2024) applies to entities collecting personal data of Oregon residents at thresholds. For biotech operators with Oregon-resident clinical trial subjects, employees, or website visitors, the OCPA creates regulatory defense and breach notification exposure layered on top of HIPAA. Cyber policies should explicitly include OCPA regulatory defense.

Are Portland-area biotech CTAs with OHSU typically tougher to negotiate?

OHSU CTAs are professional and structured but generally less aggressive than top-tier Boston AMC CTAs (MGH, Brigham, Dana-Farber). Indemnity provisions are typically more balanced. The institutional review board (IRB) process and the OHSU-side clinical research office are sophisticated, so timelines can run long, but the substantive terms are more operator-friendly than at the top East Coast clusters.

Biotech insurance practice →Biotech cyber tower structures →Seattle cell therapy (sister Pacific NW) →

Portland biotech coverage review

A specialist will reach out by end of business day.

Request the review

A specialist will reach out by the end of the day.

Programs placed through A-rated specialty markets. Your specialist handles unlimited certificates of insurance, annual coverage reviews, and claims advocacy.